Previous 10 | Next 10 |
TCR-T Library Phase 1/2 trial achieved an 87% disease control rate of eight evaluable patients with metastatic, refractory solid tumors; TCR-T cell therapy was well tolerated in all treated patients hunTR® discovered new HLA class I and class II restricted TCRs that recognize d...
INVO BioScience Inc. (INVO) is expected to report for Q3 2023 HIVE Blockchain Technologies Ltd (HIVE) is expected to report $-0.13 for Q2 2024 BioNexus Gene Lab Corp (BGLC) is expected to report for Q1 2024 Adhera Therapeutics Inc (ATRX) is expected to report for Q1 2024 Altus Pow...
Alaunos Therapeutics Inc. (TCRT) is expected to report $-0.03 for Q3 2023
2023-08-15 07:16:32 ET More on Alaunos Alaunos slips 17% on Phase 1 data for cancer cell therapy Alaunos Therapeutics upgraded to buy at Wainwright on multiple catalysts Alaunos wins bullish view at Wells Fargo on promise of cell therapy technology Alaunos ...
TCR-T Library Phase 1/2 trial achieved an 83% disease control rate of six evaluable patients with metastatic, refractory solid tumors; TCR-T cell therapy was well tolerated in all evaluable patients Company to wind down TCR-T Library Phase 1/2 trial and concurrently explore potent...
HOUSTON, June 29, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a leading T-cell receptor (TCR) cell therapy company advancing a clinical-stage pipeline of therapeutics for solid tumors, today announced that the Compan...
2023-05-26 15:36:17 ET Alaunos Therapeutics ( NASDAQ: TCRT ) fell ~17% on Friday as investors reacted to data from a Phase 1/2 trial for its T-cell receptor (TCR) cell therapy candidate in patients with solid tumors harboring KRAS or TP53 genetic mutations. As of Feb. 2023, ...
TCR-T cell therapy shows first-in-human response for non-viral TCR-T therapy; effectively targets high frequency TP53 and KRAS driver mutations across multiple solid tumor indications Treatment was well tolerated with a manageable safety profile and persistence of TCR-T cells in perip...
2023-05-10 15:40:23 ET Alaunos Therapeutics, Inc. (TCRT) Q1 2023 Earnings Conference Call May 10, 2023 09:00 AM ET Company Participants Alex Lobo - Stern Investor Relations Kevin Boyle - Chief Executive Officer Drew Deniger - Vice President of Research & Deve...
2023-05-10 07:09:24 ET Alaunos Therapeutics press release ( NASDAQ: TCRT ): Q1 GAAP EPS of -$0.04 in-line. As of March 31, 2023, Alaunos had approximately $37.4 million in cash balances, which included restricted cash of approximately $13.9 million. Based on current op...
News, Short Squeeze, Breakout and More Instantly...
Alaunos Therapeutics Inc. Company Name:
TCRT Stock Symbol:
NASDAQ Market:
Alaunos Therapeutics Inc. Website:
A look at the top 10 most actives in the United States Onconetix Inc. (ONCO) rose 46.5% to $0.2183 on volume of 404,016,812 shares NVIDIA Corporation (NVDA) rose 2.6% to $121.09 on volume of 317,123,916 shares PROSHARES TRUST (SQQQ) rose 1.5% to $8.23 on volume of 207,449,647 shares Max...
Iochpe-Maxion S.A. ADR (IOCJY) is expected to report for quarter end 2023-12-31 The Alkaline Water Company Inc. (WTER) is expected to report for Q3 2024 Clover Leaf Capital Corp. (CLOE) is expected to report for Q4 2023 Silvergate Capital Corporation Class A (SICP) is expected to repo...